Acta OncologicaPub Date : 2025-07-21DOI: 10.2340/1651-226X.2025.43700
Evelina Gille, Anders Näsman, Madeleine Helmersson, Elin Marsk, Antti Mäkitie, Lalle Hammarstedt-Nordenvall
{"title":"The burden and outcome of nasopharyngeal carcinoma in Sweden.","authors":"Evelina Gille, Anders Näsman, Madeleine Helmersson, Elin Marsk, Antti Mäkitie, Lalle Hammarstedt-Nordenvall","doi":"10.2340/1651-226X.2025.43700","DOIUrl":"10.2340/1651-226X.2025.43700","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study is to present the nationwide disease burden and survival of nasopharyngeal carcinoma (NPC) in Sweden. The subcohort from the Stockholm-Gotland region was included to investigate the prevalence of Epstein-Barr virus (EBV) in NPC and to describe pattern of relapse.</p><p><strong>Methods: </strong>This population-based nationwide study included patients diagnosed with NPC in Sweden during 2008-2021. The series was retrieved from the Swedish Head and Neck Cancer Register. Age at diagnosis, sex, tumor histopathology, stage, treatment intent, treatment, radiation dose, follow-up time, time to relapse, and site of relapse were recorded. The Stockholm-Gotland region series was used to obtain an updated histopathological analysis including EBV status and to analyze site of relapse.</p><p><strong>Results: </strong>The nationwide study cohort comprised 399 patients, 33% were female. Mean age at diagnosis did not differ between the sexes: 56.3 years for females, 57.5 years for males. Seventy-one percent presented with Stage III or IV. The 5-year overall survival (OS) was 73.2%. In the regional cohort, 73.9% were EBV positive. In the competing risk analysis, the cumulative incidence of distant metastatic relapse was higher than that of local and/or regional relapse at 5 years (18.7% vs. 12.4%). However, the confidence intervals were wide, and the difference should be interpreted with caution.</p><p><strong>Interpretation: </strong>The survival outcome in our study seems comparable to previous studies in nonendemic countries. There was a high percentage of EBV-positive tumors compared with the previous studies in nonendemic countries.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"894-901"},"PeriodicalIF":2.7,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prediction model for the selection of patients with glioma to proton therapy.","authors":"Jesper Folsted Kallehauge, Siri Grondahl, Camilla Skinnerup Byskov, Morten Høyer, Slavka Lukacova","doi":"10.2340/1651-226X.2025.43883","DOIUrl":"10.2340/1651-226X.2025.43883","url":null,"abstract":"<p><strong>Background and purpose: </strong>The selection of patients with low-grade gliomas for proton therapy (PT) is often based on the comparison of photon and PT plans and demonstrating meaningful dose reduction to the healthy brain or critical structures. The aim of this retrospective study was to identify clinical parameters associated with referral to PT and build a prediction model.</p><p><strong>Patients and methods: </strong>The dataset consisted of patients with isocitrate dehydrogenase (IDH)-mutant grades 2 and 3 glioma and candidates for PT at the Aarhus University Hospital. Clinical (age, diagnosis, clinical target volume [CTV], and treatment) and dosimetric (prescribed dose and mean dose (Dmean) to healthy brain) parameters were collected. Univariate and multivariate logistic regression were used to assess the association with selection for PT. The dataset was split into training (n = 37, period 2019-2022) and test (n = 12, period 2023) cohorts. Prediction models were built using logistic regression algorithms and support vector machines (SVMs) and evaluated using the area under the precision-recall curve (AUC-PR).</p><p><strong>Results: </strong>Age (p = 0.03) and CTV (p = 0.01) were significantly associated with the selection for PT and were used for model prediction. The logistic regression demonstrated AUC-PR at 0.999 (CI 0.999-1.000) and 0.998 (0.996-1.000) for training and test cohorts, respectively. SVM showed similar results with AUC-PR at 0.993 (0.993-0.994) for training and 0.999 (0.998-1.000) for test cohorts.</p><p><strong>Interpretation: </strong>Logistic regression and SVM using age and CTV performed equally well and achieved a very high positive predictive value. With the pending external validation in a larger dataset, the prospects of this work suggest more consistent and efficient patient referral for PT.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"889-893"},"PeriodicalIF":2.7,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acta OncologicaPub Date : 2025-07-10DOI: 10.2340/1651-226X.2025.43912
Anne Wilhøft Kristensen, Kenneth Jensen, Annesofie L Jensen, Susanne O Dalton, Jesper Eriksen, Jeppe Friborg, Cai Grau
{"title":"Factors associated with participation in a proton therapy clinical trial: a cross-sectional survey of Danish patients with head and neck cancer.","authors":"Anne Wilhøft Kristensen, Kenneth Jensen, Annesofie L Jensen, Susanne O Dalton, Jesper Eriksen, Jeppe Friborg, Cai Grau","doi":"10.2340/1651-226X.2025.43912","DOIUrl":"10.2340/1651-226X.2025.43912","url":null,"abstract":"<p><strong>Background and purpose: </strong>Participation in proton therapy (PT) trials may be affected by structural, clinical, and individual factors, potentially excluding certain patient groups. Such disparities can lead to unequal access to potential research benefits and may limit the generalisability of trial findings. This study aimed to identify factors associated with participation in a Danish randomised controlled trial (RCT) comparing proton versus photon radiotherapy for head and neck cancer.</p><p><strong>Patients and methods: </strong>This national cross-sectional study invited patients with pharyngeal and laryngeal cancer, referred for curative-intent radiotherapy at seven Danish radiotherapy clinics between 2022 and 2025, to complete a survey. Respondents were categorised based on enrollment status in a national RCT comparing proton versus photon radiotherapy. Clinical, demographic, psychosocial, and lifestyle data were collected and linked to clinical registry data. Multiple logistic regression was used to assess exposure variables associated with trial participation.</p><p><strong>Results: </strong>Of 304 respondents, 120 (39%) were enrolled in the RCT. Female gender, older age, greater geographical distance to the PT centre, mobility limitations, lower self-rated health status, and lower ability to actively engage with healthcare providers (Health Literacy Questionnaire scale 6) were significantly associated with lower odds of participation. No significant associations were observed for income, education, marital status, or anxiety.</p><p><strong>Interpretation: </strong>The findings indicate that demographic, geographical, functional, and communication--related factors may limit participation in PT trials. This highlights the need for interventions that enhance the delivery of trial information, strengthen communication between patients and healthcare professionals, and support informed clinical trial decision-making.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"879-888"},"PeriodicalIF":2.7,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acta OncologicaPub Date : 2025-07-09DOI: 10.2340/1651-226X.2025.43897
Odd Terje Brustugun, Erik Waage Nielsen
{"title":"Acquired angioedema and rituximab-induced acute thrombocytopenia in splenic marginal zone lymphoma.","authors":"Odd Terje Brustugun, Erik Waage Nielsen","doi":"10.2340/1651-226X.2025.43897","DOIUrl":"10.2340/1651-226X.2025.43897","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"868-871"},"PeriodicalIF":2.7,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acta OncologicaPub Date : 2025-07-09DOI: 10.2340/1651-226X.2025.43825
Morten Nielsen, Mai-Britt Linaa, Vibeke Nordmark Hansen, Laura Patricia Kaplan, Mikkel Drøgemüller Lund, Martin Skovmos Nielsen, Wiviann Ottoson, Cécile Peucelle, Laura Ann Rechner, Heidi S Rønde, Tine Schytte, Weronika Maria Szejniuk, Rebecca Jean Tobin, Lone Hoffmann, Ane Appelt
{"title":"A comprehensive national audit of radiotherapy retreatment numbers, sites and indications.","authors":"Morten Nielsen, Mai-Britt Linaa, Vibeke Nordmark Hansen, Laura Patricia Kaplan, Mikkel Drøgemüller Lund, Martin Skovmos Nielsen, Wiviann Ottoson, Cécile Peucelle, Laura Ann Rechner, Heidi S Rønde, Tine Schytte, Weronika Maria Szejniuk, Rebecca Jean Tobin, Lone Hoffmann, Ane Appelt","doi":"10.2340/1651-226X.2025.43825","DOIUrl":"10.2340/1651-226X.2025.43825","url":null,"abstract":"<p><strong>Background and purpose: </strong>Reirradiation has seen increased interest and clinical use; however, robust data on patient numbers and treatment indications are missing. As a precursor to a prospective national reirradiation registry, a comprehensive national audit of reirradiation was performed.</p><p><strong>Patients/materials and methods: </strong>Radiotherapy retreatment courses in 2023 were audited by all (eight) radiotherapy centres in Denmark. Six centres extended the evaluation to include 2021-22, and three of these also evaluated preceding years. Reirradiation was defined according to the ESTRO/EORTC consensus (i.e. treatment volume overlap or cumulative dose toxicity risk) using 3 months threshold between the primary and reirradiation courses. Reirradiation courses were further stratified into curative/ablative and palliative treatments by prescription dose.</p><p><strong>Results: </strong>The total number of radiotherapy patients at Danish centres in 2023 was 17,424. Of these, 3,163 received retreatment, including 1,471 reirradiation courses (1,035 palliative; 436 curative/ablative). From 2014 to 2023, absolute numbers for both retreatment and reirradiation increased. We found large variation in prescription doses and fractionation schedules used for reirradiation. Widely used palliative prescriptions were 8Gy/1 fraction (F), 20Gy/4F and 30Gy/10F; stereotactic prescriptions of 20Gy/1F or 27Gy/3F in brain and 45Gy/3F in lung; and a variety of curative treatments schedules. Palliative reirradiations were primarily thoracic (29%), spine (25%), and abdominal/pelvic (22%) and curative/ablative reirradiations were primarily breast (29%) and lung stereotactic (23%).</p><p><strong>Interpretation: </strong>This is the first comprehensive national audit of reirradiation, demonstrating an increasing number of patients being treated, using a wide variety of dose prescriptions and fractionation schedules.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"872-878"},"PeriodicalIF":2.7,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acta OncologicaPub Date : 2025-07-03DOI: 10.2340/1651-226X.2025.43469
Teija Nieminen, Morag Tolvi, Tuija Ylä-Kotola, Lasse Lehtonen, Antti Mäkitie, Taru Ilmarinen
{"title":"Risk factors for early mortality and impaired quality of life in oral cavity cancer - head and neck cancer register study.","authors":"Teija Nieminen, Morag Tolvi, Tuija Ylä-Kotola, Lasse Lehtonen, Antti Mäkitie, Taru Ilmarinen","doi":"10.2340/1651-226X.2025.43469","DOIUrl":"10.2340/1651-226X.2025.43469","url":null,"abstract":"<p><strong>Background and purpose: </strong>Treatment of locoregionally advanced oral cavity cancer (OCC) is associated with treatment-related complications, functional deficits, and even early mortality. High-quality register data could help in choosing between curative and non-curative intent treatment options.</p><p><strong>Materials and methods: </strong>The Helsinki Head and Neck Cancer Register (HHNCR) is linked with the EORTC QLQ-H&N35 questionnaire automatically sent to all patients at diagnosis and predetermined intervals. We analyzed pretreatment data of all patients diagnosed with OCC during 2018-2023, focusing on risk factors for early mortality and impaired health-related quality of life after curative-intent treatment.</p><p><strong>Results: </strong>Of 597 patients, 556 (93%) were treated with curative intent. Thirty-nine (7.0%) patients died within 6 months after diagnosis. The independent risk-factors for 6-month mortality identified in multivariable analysis were T3 stage (OR 8.3 [2.6-26.5], p < 0.001), T4 stage (OR 8.2 [2.5-26.8], p < 0.001), N3 stage (OR 10.6 [3.2-35.1], p < 0.001), and Adult Comorbidity Evaluation (ACE)-27 score 2-3 (OR 5.5 [2.4-12.5], p < 0.001). These risk-factors were used to create a predictive risk score for early death. Younger, healthier patients had significantly higher EORTC QLQ-H&N35 response rates compared with older patients with comorbidities. Six months after diagnosis, patients with a stage III-IV tumor had significantly higher scores in 15 of 18 items, compared with patients with a stage I-II tumor.</p><p><strong>Interpretation: </strong>Early mortality was associated with advanced tumor (T) and nodal (N) stage, and increased pretreatment comorbidity (ACE-27) scores. The strongest predictor for impaired quality of life was locoregionally advanced disease.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"859-867"},"PeriodicalIF":2.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acta OncologicaPub Date : 2025-07-02DOI: 10.2340/1651-226X.2025.44082
Umar Aziz
{"title":"The risk of myelodysplastic syndrome and acute myeloid leukemia by metformin use and type 2 diabetes status - a Danish nation-wide cohort study.","authors":"Umar Aziz","doi":"10.2340/1651-226X.2025.44082","DOIUrl":"10.2340/1651-226X.2025.44082","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"857-858"},"PeriodicalIF":2.7,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144537683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acta OncologicaPub Date : 2025-07-02DOI: 10.2340/1651-226X.2025.43208
Linda Thorén, Jonatan D Lindh, Espen Molden, Marianne Kristiansen Kringen, Jonas Bergh, Erik Eliasson, Sara Margolin
{"title":"CYP2D6 genotype and outcome in tamoxifen treated early breast cancer.","authors":"Linda Thorén, Jonatan D Lindh, Espen Molden, Marianne Kristiansen Kringen, Jonas Bergh, Erik Eliasson, Sara Margolin","doi":"10.2340/1651-226X.2025.43208","DOIUrl":"10.2340/1651-226X.2025.43208","url":null,"abstract":"<p><strong>Background and purpose: </strong>The clinical significance of individual CYP2D6 activity for the outcome of tamoxifen treatment in early breast cancer is unclear. Our previous investigation in patients diagnosed over the period 1998-2000 indicated an association between reduced CYP2D6 activity and poor outcome in premenopausal women. The aim of this study was to investigate the association between CYP2D6 genotype and clinical outcome in a larger tamoxifen treated cohort.</p><p><strong>Patients/material and methods: </strong>Swedish breast cancer patients who initiated adjuvant tamoxifen treatment over the period 2006-2014 constituted the full study cohort. Clinical information was collected from medical records. Data on endocrine treatment, use of CYP2D6 inhibitors was retrieved from the Swedish Prescribed Drug Register. CYP2D6 was genotyped and translated into predicted metabolic activity. The association between CYP2D6 activity and clinical outcome was analyzed using Cox regression, controlling for potential confounding variables. Subgroup analyses were performed based on menopausal status, tamoxifen treatment for at least 1 year and as single endocrine treatment, HER2-status and tamoxifen monotherapy.</p><p><strong>Results: </strong>A total of 1,103 patients were included. A total of 761 patients received tamoxifen as monotherapy. A total of 42% were premenopausal. Median follow-up was 11.4 years. No significant association was found between CYP2D6 activity and recurrence (adjusted hazard ratio [aHR] 1.18, 95% CI 0.92; 1.52) or breast cancer mortality (aHR 1.41, 95%CI 0.93; 2.13) in the full cohort, or in the subgroup with tamoxifen monotherapy (aHR 1.39, CI 0.99; 1.96 and 1.88, CI 0.98; 3.60 respectively).</p><p><strong>Interpretation: </strong>No association was noted between reduced CYP2D6 activity and poorer outcome in this early breast cancer cohort, with patients generally at lower risk of recurrence, reflecting the role of adjuvant tamoxifen in current clinical practice.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"848-856"},"PeriodicalIF":2.7,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144537681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acta OncologicaPub Date : 2025-07-02DOI: 10.2340/1651-226X.2025.43089
Anne Dyhl-Polk, Morten Schou, Kirsten K Vistisen, Anne-Sophie Sillesen, Stig E Bojesen, Jens Faber, Merete Vaage-Nilsen, Dorte L Nielsen
{"title":"Incidence of myocardial ischemia during treatment with capecitabine: a cohort study with Holter recording and cardiac biomarkers.","authors":"Anne Dyhl-Polk, Morten Schou, Kirsten K Vistisen, Anne-Sophie Sillesen, Stig E Bojesen, Jens Faber, Merete Vaage-Nilsen, Dorte L Nielsen","doi":"10.2340/1651-226X.2025.43089","DOIUrl":"10.2340/1651-226X.2025.43089","url":null,"abstract":"<p><strong>Background and purpose: </strong>Treatment with fluoropyrimidines can lead to cardiotoxicity. For 5-fluorouracil, silent myocardial ischemia and effort-related myocardial ischemia have been demonstrated. We investigated the incidence of myocardial ischemia and clinical cardiotoxicity during treatment with capecitabine, a pro-drug of 5-fluorouracil.</p><p><strong>Patients and methods: </strong>We included patients with breast- or colorectal cancer, who received first-time treatment with capecitabine. Holter recording, clinical evaluation, 12-lead electrocardiogram, and measurement of plasma cardiac troponin I and copeptin were performed before and during treatment.</p><p><strong>Results: </strong>A total of 42 patients with breast cancer and 39 with colorectal cancer were included. Seven patients (9%) experienced clinical cardiotoxicity; five with unstable angina, one with dyspnoea, ST elevations and anterolateral hypokinesia, and one with cardiac arrest. Six patients (8%) had myocardial ischemia on Holter recording during treatment. Among these were two with clinical cardiotoxicity, and four (5.0%) with silent myocardial ischemia. More patients had myocardial ischemia on Holter recording during treatment compared to before, but the difference was not statistically significant (1st cycle: p = 0.22, 3rd/4th cycle: p = 0.50). Plasma copeptin increased during 1st cycle (p = 0.004), while cardiac troponin I remained unchanged (p = 0.92). More patients had non-sustained ventricular tachycardia during 1st cycle of treatment than before (p = 0.020).</p><p><strong>Interpretation: </strong>Treatment with capecitabine was associated with an incidence of myocardial ischemia of 8%, an incidence of clinical cardiotoxicity of 9%, and an increase in plasma copeptin and the frequency of non-sustained ventricular tachycardia episodes. Increases in cardiac troponin I were rare. The incidence of myocardial ischemia was lower than previously reported for 5-fluorouracil.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"837-847"},"PeriodicalIF":2.7,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144537682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acta OncologicaPub Date : 2025-06-29DOI: 10.2340/1651-226X.2025.43328
Katja M Mustonen, Maarit H Lamminmäki, Tytti M Sarkeala, Sirpa H Heinävaara
{"title":"Prostate cancer incidence and mortality among immigrants in Finland between 2000 and 2017 - a register-based cohort study.","authors":"Katja M Mustonen, Maarit H Lamminmäki, Tytti M Sarkeala, Sirpa H Heinävaara","doi":"10.2340/1651-226X.2025.43328","DOIUrl":"10.2340/1651-226X.2025.43328","url":null,"abstract":"<p><strong>Background and purpose: </strong>Prostate cancer impacts millions of men worldwide each year, and its significance will continue to rise as populations age. Literature demonstrates differences in cancer burden between immigrant groups and non-immigrants across the world. Despite its prevalence, little research has focused primarily on prostate cancer among immigrants.</p><p><strong>Patients/material and methods: </strong>We utilized individual-level data on all immigrant men who had lived in Finland for over a year between 1973 and 2017 and aggregate data on Finnish-born men to determine immigrants' incidence of and mortality from prostate cancer in relation to the men born in Finland. This gave us a study population of 162,844 non-Western and 56,127 Western immigrant men. Cases and deaths from the study period (2000-2017) were analyzed with the multivariate Poisson regression model for the groups, non-Western and Western immigrants separately.</p><p><strong>Results and interpretation: </strong>Non-Western men had a relative risk (RR) of 0.663 (95% confidence interval [CI] 0.609-0.722) for cases and 0.803 (0.646-0.997) for deaths. Western men had RRs of 0.876 (0.784-0.978) and 0.78 (0.567-1.072), respectively. A longer duration of residence and a younger age at immigration increased the risk for prostate cancer. Compared to the men born in Finland, both immigrant groups showed a lower risk of prostate cancer. Non-Western men may have also had a lower risk of death from it. Prostate cancer mortality in non-Western immigrants appears to be high compared to its incidence. While uncertain, this implication is concerning enough to warrant further research into the topic.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"830-836"},"PeriodicalIF":2.7,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144525972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}